CatalYm GmbH
Overview
CatalYm GmbH is developing an immune therapy for solid tumors by neutralizing GDF-15, a mechanism that cancer cells use to resist therapy. The company is advancing its lead antibody, Visugromab, into Phase 2b studies.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to CatalYm GmbH in our records. PharmaTek screens the full directory against live FDA enforcement data.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.